Disclosures for "Pharmacological Interventions for Pain Management in Diabetic Peripheral Neuropathy: A Network Meta-analysis of Randomised Controlled Trials"
-
Mr. Suresh has nothing to disclose.
-
Mr. Dey has nothing to disclose.
-
Miss Jayan has nothing to disclose.
-
Dr. Shamim has nothing to disclose.
-
Miss Gupta has nothing to disclose.
-
Mr. RAMANA has nothing to disclose.
-
Mr. Dave has nothing to disclose.
-
Mr. Jena has nothing to disclose.
-
Mr. Muneer has nothing to disclose.
-
Dr. Dhakal has nothing to disclose.
-
Mr. Ghosh has nothing to disclose.
-
Mr. Verma has nothing to disclose.
-
Mr. Garg has nothing to disclose.
-
Mr. Muzammil has nothing to disclose.
-
Dr. Bardhan has nothing to disclose.
-
Dr. Malhotra has nothing to disclose.
-
Dr. Kumar has nothing to disclose.
-
Dr. Mallick has nothing to disclose.
-
Dr. Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda Pharmaceuticals. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for argenx. Dr. Roy has stock in Cabaletta bio. . The institution of Dr. Roy has received research support from Martin Shubik Fund for IBM at Yale University. The institution of Dr. Roy has received research support from Abcuro Pharmaceuticals.